Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics - Narrative (Details)

v3.21.1
Acquisition of Pelican Therapeutics - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2016
May 31, 2016
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2018
Dec. 31, 2020
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Acquisition of Pelican Therapeutics                  
Discount rate     8.07%            
Accrued liabilities     $ 1,764,385     $ 1,614,534      
Other income     (168,355) $ (257,479)          
Revenue     538,645 901,880          
Net loss attributable to Heat Biologics, Inc.     (7,532,178) (6,292,106)          
Net loss     $ 7,623,140 $ 6,373,420          
Pelican Therapeutics, Inc.                  
Acquisition of Pelican Therapeutics                  
Ownership interest in subsidiary     85.00%     85.00%      
Pelican Therapeutics, Inc.                  
Acquisition of Pelican Therapeutics                  
Percentage of voting interests acquired in acquisition             85.00% 80.00% 80.00%
Cash consideration         $ 200,000        
Percentage of non-controlling interest acquired     20.00%            
Amount awarded from CPRIT grant   $ 15,200,000              
Pelican Therapeutics, Inc. | Maximum                  
Acquisition of Pelican Therapeutics                  
Amount awarded from CPRIT grant $ 15,200,000                
Pelican Therapeutics, Inc. | Stockholders                  
Acquisition of Pelican Therapeutics                  
Cash consideration         $ 300,000        
Pelican Therapeutics, Inc. | CEO                  
Acquisition of Pelican Therapeutics                  
Percentage of milestone payments that will be paid to related parties         22.70%